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Nonmelanomatous Skin
Cancer Following Cervical,
Vaginal, and Vulvar
Neoplasms: Etiologic
Association
Human papillomavirus infection is
the major cause of cancers of the cervix,
vagina, and vulva (1). Nonmelanoma-
tous skin cancers have been associated
with human papillomavirus infection
in patients with epidermodysplasia ver-
ruciformis and in patients who are im-
munosuppressed or nonimmunosup-
pressed, although the data are scant
(1,2).
We used the cancer registry of the
Swiss Canton of Vaud (with a popula-
tion of approximately 600 000 in 1990)
for the period from 1974 through 1994
to obtain additional quantitative infor-
mation on this topic, which has patho-
genic and public health implications.
Data were collected for women who had
in situ or invasive neoplasms of the cer-
vix, vagina, or vulva and for women
who had nonmelanomatous skin cancer.
These data were then used to calculate
the incidence of nonmelanomatous skin
cancer in women who had been regis-
tered with an in situ or invasive neo-
plasm of the cervix, vagina, or vulva (3).
The registry is tumor based, and mul-
tiple primary tumors in the same person
are entered separately. The basic infor-
mation available consists of sociodemo-
graphic characteristics of the patient, the
primary site of the tumor, the histologic
type of the tumor according to the stan-
dard International Classification of Dis-
eases (ICD) for Oncology (4), and the
time of diagnostic confirmation. Passive
and active follow-ups are recorded, and
each subsequent item of information
concerning a registered cancer is used to
complete the record of that patient.
Since 1974, a registration scheme
that applies the standardized rules used
for incident cancers has been used for
carcinoma in situ and severe dysplasia
(CIN III, cervical intraepithelial neopla-
sia III) of the uterine cervix (ICD code:
180.0–180.9), vagina (ICD: 184.0), and
vulva (ICD: 184.1–184.3) (4).
In the present study, when all syn-
chronous neoplasms were excluded,
there were 2339 histologically con-
firmed cases of carcinoma in situ of the
cervix uteri, nine cases of carcinoma in
situ of the vagina, and 85 cases of car-
cinoma in situ of the vulva. The study
also included 789 cases of invasive neo-
plasms of the cervix, 69 cases of inva-
sive neoplasms of the vagina, and 153
cases of invasive neoplasms of the
vulva. These cases were followed to the
end of 1996 for the occurrence of can-
cer, migration, or death.
We calculated the expected numbers
of individuals with nonmelanomatous
skin cancer based on site-, age-, and cal-
endar-period-specific incidence rates,
multiplied by the observed number of
person-years at risk. The statistical sig-
nificance of the observed/expected ra-
tios (standardized incidence ratio [SIR])
and the corresponding 95% confidence
interval (CI) were based on the Poisson
distribution.
Table 1 gives the observed and ex-
pected numbers of nonmelanomatous
skin neoplasms after diagnosis of in
situ or invasive neoplasms of the cer-
vix, vagina, and vulva. A statistically
significant excess of skin cancer was
registered after cervical neoplasms
(44 observed and 24 expected; SIR 4
1.8; 95% CI 4 1.3–2.5) and vulvar
neoplasms (13 observed and four ex-
pected; SIR 4 3.2; 95% CI 4 1.7–5.5).
Likewise, three nonmelanomatous
skin cancers were observed after
vaginal neoplasms versus one expected
(SIR 4 2.9; 95% CI 4 0.6–8.6). Over-
all, 60 skin cancers were observed ver-
sus 29 expected (SIR 4 2.1; 95% CI 4
1.6–2.7).
An excess of nonmelanomatous skin
cancer after diagnosis of carcinoma
in situ of the cervix has been reported
(5,6). The present data extend this
observation to other neoplasms of
the lower female genital tract and, there-
fore, provide epidemiologic support to
the suggestion of a possible role of human
papillomavirus infection in the etiology of
nonmelanomatous skin cancer (7).
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Table 1. Observed and expected cases, in Vaud, Switzerland, from 1974 through 1994, and
standardized incidence ratios (SIRs) of subsequent nonmelanomatous skin cancer after an initial
diagnosis of in situ or invasive neoplasms of the cervix, vagina, and vulva, as well as the
corresponding 95% confidence intervals (CIs)
Site of in situ or
invasive primary tumor
No. of nonmelanomatous skin cancers
SIR (95% CI)Observed Expected
Cervix (n 4 3128) 44 24 1.8
(1.3–2.5)
Vagina (n 4 78) 3 1 2.9
(0.6–8.6)
Vulva (n 4 238) 13 4 3.2
(1.7–5.5)
Total (n 4 3444) 60 29 2.1
(1.6–2.7)
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Re: Distinguishing Second
Primary Tumors From Lung
Metastases in Patients With
Head and Neck Squamous
Cell Carcinoma
The recent paper by Leong et al. (1)
highlights progress regarding a long-
standing oncology dilemma in distin-
guishing a solitary metastatic deposit
from a new cancer in patients with
known prior cancer. The specific clini-
cal scenario is familiar to those who fre-
quent head and neck tumor boards—
specifically, the patient with known
head and neck cancer (squamous cell
carcinoma) who simultaneously or sub-
sequently manifests a solitary pulmo-
nary nodule, which is similarly con-
firmed as squamous cell carcinoma.
Many head and neck oncologists
have turned wistfully toward their tumor
board pathologist with the simple ques-
tion, ‘‘Is this a metastasis or a new pri-
mary tumor?’’ The promise of this pub-
lished work by Leong et al. (1) is that we
are moving closer to providing the cli-
nician with molecular diagnostic tools to
answer the question more precisely.
Judicious application of molecular
techniques to complement clinical judg-
ment in the ‘‘metastasis versus primary
tumor’’ scenario will clearly prove ben-
eficial in selected circumstances. Never-
theless, maximizing clinical thinking be-
fore soliciting molecular ‘‘truth telling’’
will be important. In their abstract,
Leong et al. state ‘‘. . . a solitary SCC
[squamous cell carcinoma] in the lung
more likely represents a metastasis than
an independent lung cancer.’’ However,
this is largely dependent on the patient
cohort selected. The study group in the
paper by Leong et al. is dominated by
patients with advanced, lymph node-
positive, and/or recurrent head and neck
cancers. Of the 16 patients studied, 13
presented with stage IV tumors and 15
were lymph node positive at presenta-
tion. These represent compelling prog-
nostic features for locoregional disease
recurrence and eventual distant metasta-
ses. Thus, it is not surprising that 12 of
16 lung tumors appeared to represent
metastases in this group of patients with
highly advanced-stage disease for whom
clinical judgment would largely dictate
the same. This is by no means meant to
detract from the importance of this work.
Rather, it is suggested that such molecular
analysis may prove far more important in
patients with earlier stage disease for
whom the clinical likelihood of distant
metastasis is deemed far lower.
Approximately one quarter to one
third of the patients with head and neck
cancer present with stage I or stage II
disease (lymph node negative); in these
patients, lung metastases would be dis-
tinctly unusual. For these patients, the
cost of mistakenly assuming a meta-
static process could be tragic, and the
value of confirming a molecular distinc-
tion may be critical to optimizing
therapy recommendations.
Leong et al. state in the ‘‘Discus-
sion’’ section, ‘‘Most solitary lung nod-
ules in patients with HNSCC [head and
neck squamous cell carcinoma] may ac-
tually reflect advanced tumor spread.’’
These authors would not wish to inad-
vertently mislead the general oncologist
into thinking that this is true for all pa-
tients with head and neck cancer. This
conclusion is strongly influenced by the
clinical staging of the original tumors. A
molecular examination of 16 patients
with early stage head and neck tumors
who manifest solitary pulmonary nod-
ules might well lead others to draw the
opposite conclusion. Nevertheless, these
advances in tumor fingerprinting will
surely provide tangible benefits to se-
lected cancer patients in whom the judi-
cious application of molecular data will
complement and clarify clinical judgment.
PAUL M. HARARI
REFERENCE
(1) Leong PP, Rezai B, Koch WM, Reed A, Eisele
D, Lee DJ, et. al. Distinguishing second pri-
mary tumors from lung metastases in patients
with head and neck squamous cell carcinoma.
J Natl Cancer Inst 1998;90:972–7.
NOTE
Correspondence to: Paul M. Harari, M.D., De-
partment of Human Oncology, 600 Highland Ave.
K4/B100, Madison, WI 53792-0600.
RESPONSE
We welcome Dr. Harari’s refreshing
embrace of a novel strategy for the reso-
lution of a long-standing oncologic
impasse. Comparative microsatellite
analysis is a highly effective tool in dis-
tinguishing second lung tumors from
lung metastasis. No doubt, similar ge-
netic strategies addressing equally rel-
evant clinical issues will play an in-
creasing role in the integrated multidisci-
plinary approach to patients with head and
neck squamous cell carcinoma (HNSCC)
and cancers at other sites.
As always, caution and discretion
must be exercised when generalizing
study results to the individual patient.
Our study reflects the experience of a
large tertiary care center where patients
are often referred for management of ad-
vanced HNSCC. As Dr. Harari points
out, the incidence of solitary lung me-
tastases will probably be lower in pa-
tient populations over represented by
low-stage HNSCCs. For the individual
patient with HNSCC, however, micro-
satellite analysis remains a valid and
valuable tool for discerning the nature of
a solitary lung tumor. The use of such
molecular approaches is not intended to
replace sound clinical judgment but to
facilitate it.
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